Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.41, sa.12, ss.1380-1387, 2011 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 41 Sayı: 12
- Basım Tarihi: 2011
- Doi Numarası: 10.1093/jjco/hyr151
- Dergi Adı: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1380-1387
- İstanbul Üniversitesi Adresli: Evet
Özet
Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.